Literature DB >> 27313677

Correlation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic dysfunction.

Hui Gong1, Xin Wang2, Yi-Jun Shi2, Wen-Jing Shang2, Y I Ling2, Li-Jian Pan2, Hai-Ming Shi1.   

Abstract

The present study aimed to investigate the association between brain natriuretic peptide (BNP) levels and the prognosis of patients with left ventricular (LV) diastolic dysfunction. A total of 708 inpatients with cardiovascular disease (mean age, 66 years; 395 males and 313 females) were grouped according to initial BNP and were followed-up for 20-51 months (average, 30.86 months) until endpoint events occurred. Endpoints were defined as mortality or readmission due to cardiovascular disease, or mortality due to any other reason. A total of 67 and 77 events were reported in the BNP ≤80 pg/ml and BNP >80 pg/ml groups, respectively. The occurrence rate of the endpoint was significantly higher in the BNP >80 pg/ml group, as compared with the BNP ≤80 pg/ml group (26.28 vs. 16.14%; relative risk=1.63). Furthermore, the durations of patient survival were significantly shorter in the BNP >80 pg/ml group, as compared with the BNP ≤80 pg/ml group (P=0.0006), and patient survival decreased as BNP levels rose (P=0.0074). Among the 708 patients, 677 underwent echocardiographic detection at the same time. No significant correlation was detected between BNP levels and survival time in 178 patients with normal LV diastolic function [mitral Doppler flow, early diastolic (E)/late diastolic (A)>1] (P=0.2165); whereas a negative correlation was determined in 499 patients with LVD dysfunction (E/A≤1) (Spearman's rho=-0.0899; P=0.0447). The prognoses of patients with elevated BNP levels were correspondingly worse in the present study and these correlations were demonstrated to be significant in patients with LV diastolic dysfunction. Therefore, BNP levels may be used to predict the prognosis of patients with cardiovascular disease.

Entities:  

Keywords:  brain natriuretic peptide; diastolic dysfunction; prognosis

Year:  2016        PMID: 27313677      PMCID: PMC4888041          DOI: 10.3892/etm.2016.3203

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  43 in total

1.  N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.

Authors:  Torbjørn Omland; Anita Persson; Leong Ng; Russel O'Brien; Thomas Karlsson; Johan Herlitz; Marianne Hartford; Kenneth Caidahl
Journal:  Circulation       Date:  2002-12-03       Impact factor: 29.690

2.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Authors:  Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

3.  Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older.

Authors:  Patrick Ray; Martine Arthaud; Sophie Birolleau; Richard Isnard; Yannick Lefort; Jacques Boddaert; Bruno Riou
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

4.  Significance of brain natriuretic peptide in the evaluation of symptoms and the degree of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy.

Authors:  Fotis K Panou; Vasiliki K Kotseroglou; John A Lakoumentas; Stavroula A Chrysanthopoulou; John A Armeniakos; Theodora Stratigou; Helen Veve; Apostolos A Zacharoulis
Journal:  Hellenic J Cardiol       Date:  2006 Nov-Dec

5.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.

Authors:  David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

6.  Natriuretic peptide system gene expression in human coronary arteries.

Authors:  Victor H Casco; John P Veinot; Mercedes L Kuroski de Bold; Roy G Masters; Michelle M Stevenson; Adolfo J de Bold
Journal:  J Histochem Cytochem       Date:  2002-06       Impact factor: 2.479

7.  NT-proBNP levels and diastolic dysfunction in beta-thalassaemia major patients.

Authors:  Dimitrios Th Kremastinos; Dimitrios P Tsiapras; Anna G Kostopoulou; Eftihia S Hamodraka; Antigoni S Chaidaroglou; Evangelia D Kapsali
Journal:  Eur J Heart Fail       Date:  2007-02-21       Impact factor: 15.534

8.  Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP.

Authors:  Elizabeth Sykes; Raymond E Karcher; Janice Eisenstadt; David A Tushman; Mamtha Balasubramaniam; John Gusway; Valerie J Perason
Journal:  Am J Clin Pathol       Date:  2005-04       Impact factor: 2.493

9.  Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure.

Authors:  Johannes C Kelder; Frans H Rutten; Arno W Hoes
Journal:  Fam Pract       Date:  2008-12-03       Impact factor: 2.267

10.  B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.

Authors:  A Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher Frampton; John Turner; Ian G Crozier; Timothy G Yandle
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.